Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Thalassemia Intermedia Treatment & Management

  • Author: Hassan M Yaish, MD; Chief Editor: Robert J Arceci, MD, PhD  more...
 
Updated: Oct 01, 2015
 

Approach Considerations

The diagnosis of thalassemia intermedia is purely clinical and is usually made after a period of observation to determine that the patient is able to maintain a satisfactory hemoglobin (Hb) level for a long time without the need for blood transfusions. If the physician settles for a marginal level of Hb and decides not to initiate blood transfusion therapy, the patient's Hb level may fluctuate and decrease further, potentially reaching a very low level if the patient is not closely monitored. Should this occur, permanent damage, including heart failure, bone deformity, hypersplenism, liver damage, or other complications, may occur. In otherwise similar circumstances, patients with marginally severe disease should be treated in the same way as patients with thalassemia major.

Most medical care in thalassemia intermedia is provided in an outpatient setting. Inpatient care is reserved for surgical procedures such as splenectomy or resection of large extramedullary hematopoietic tumorlike masses compressing vital organs, infectious complications, or in rare severe cases that are treated by a bone marrow transplant.

Consultations

Patients in whom thalassemia is suspected should be seen and evaluated by a hematologist. In addition, consultation with the following specialists is recommended:

  • Cardiologist: For evaluation of cardiac function and monitoring of potential complications due to the anemia, transfusion, or iron overload
  • Endocrinologist: For evaluation of possible involvement of various endocrine glands, which could result in diabetes mellitus, thyroid disorder, or growth retardation
  • Gastroenterologist: For diagnosis and management of liver complications.

Activity considerations

Many patients with thalassemia intermedia should be able to tolerate most daily activities. However, once the anemia worsens, exercise intolerance develops and may represent a warning sign indicating the need for initiation of blood transfusions. Massive splenomegaly has been observed in severe cases and is a cause for limiting the patient's activity for fear of injury to the abdomen causing rupture of the spleen. Regular transfusions decrease the size of the spleen in most instances, allowing splenectomy to be avoided whenever possible.

Next

Clinical Management

The treatment of most cases of thalassemia intermedia involves close monitoring and observation. Patients with satisfactory hemoglobin (Hb) levels are frequently monitored. These patients usually require blood transfusions only on certain occasions such as the presence of intercurrent infections, hypersplenism, or other illnesses.

If patients can no longer maintain an Hb level of more than 6 g/dL, they are either started on a regimen of regular blood transfusions or a different option, such as splenectomy, should be tried. Patients with evidence of hypersplenism have a good chance to have their need for blood transfusion reduced or totally eliminated; this might last for months or years.

Inducing erythropoiesis

Administration of one of the drugs that may induce stress erythropoiesis and raise Hb levels may be tried. Hydroxyurea has been frequently used for this purpose. In separate studies on a large number of patients, a response rate exceeding 75% was reported after long-term therapy.[29] However, this high rate of response was not confirmed by other studies until a study on a small number of patients with β thalassemia major and intermedia treated with hydroxyurea demonstrated a response rate of more than 82%.[30]

Marrow suppression and cytopenia could be a real concern in patients receiving hydroxyurea. In searching for new agents without such adverse effects, pomalidomide was found to augment fetal hemoglobin production in mice without the myelosuppression effect of hydroxyurea. Further evaluation of this agent for possible clinical application is warranted.[31]

Blood transfusions

Many studies have shown that patients with thalassemia intermedia who are not on regular blood transfusion because of their milder symptoms nevertheless develop major complications related to their chronic anemia and ineffective erythropoiesis (IE). Considering the cost-benefit balance of regular treatment in patients with thalassemia major, most patients with thalassemia intermedia would apparently benefit from similar therapy to prevent the complications, rather than waiting to deal with such complications when they occur.

The initial regimen includes transfusion of 10-15 mL of packed red blood cells (PRBCs) every 4-5 weeks to keep the Hb level over 10 g/dL. Blood transfusions should be leukocyte poor to avoid sensitization, because such patients have the potential of becoming transfusion dependent in the future. Patients should be checked and typed for minor blood groups to avoid further difficulties in providing appropriate blood for them in the future. Identification of a small group of dedicated donors minimizes the risk of viral exposure and alloimmunization. (See also Transfusion and Autotransfusion, Transfusion-Induced Iron Overload, Alloimmunization From Transfusions, and Transfusion Reactions.)

Chelation therapy

Iron status must be carefully monitored, and patients with iron overload should be treated with an aggressive chelation regimen as soon as indicated. A previously popular chelation regimen includes administration of deferoxamine 5 days per week as a subcutaneous (SC) infusion over 8-12 hours. This regimen had revolutionized the treatment of β thalassemia major in patients regularly receiving PRBC transfusions and resulted in longer survival and near-normal quality of life.

An oral iron chelator, deferasirox (Exjade), has been in use in the United States for some time. This agent has a long half-life and, for this reason, is orally (PO) administered once daily. Several studies have confirmed the long-term efficacy and safety of this agent. It is now much more popular relative to deferoxamine and, due to the ease and convenience of administration and better compliance, is probably replacing deferoxamine.[32]

A similar dose is often administered at the time of blood transfusions to help bind the transfused iron (from hemolyzed RBCs).

A 5-year prospective European study[33] reported on 555 children and adults who were divided into 2 groups, the first treated with deferasirox for a total of 5 years (deferasirox cohort) and the second started on deferoxamine for the first year then switched to deferasirox (cross-over cohort). At the end of the treatment period, a liver biopsy was obtained and HIC was measured in the 2 groups and compared with the initial level before treatment. In the deferasirox cohort, HIC decreased by 7.8 ±11.2 mg Fe/g dry weight. In the cross-over cohort, the decrease was somewhat less, at 3.1 ±7.9 mg Fe/g dry weight.

These findings support the long-term efficacy of this oral chelating agent, which also was proven to be safe with only minimal adverse effects reported, including increased blood creatinine in 11.2%, abdominal pain in 9%, and nausea in 7.4%. No adverse effects on growth in children or sexual development in adolescents were noted.[33]

In January 2013, the FDA approved deferasirox (Exjade) for treatment of chronic iron overload caused by nontransfusion-dependent thalassemia. Deferasirox is a selective trivalent iron chelator that reduces liver iron concentration (LIC) and serum ferritin levels. Approval was based on two clinical trials that measured the number of patients whose LIC was reduced to < 5 mg/g dry weight after 52 weeks of treatment. In the first trial, 166 patients received 5 mg/kg or 10 mg/kg of deferasirox, or a placebo daily. Results showed 15% and 27% of deferasirox-treated patients, respectively, achieved the target LIC compared with 4% of placebo-treated patients.[34] The second trial included 133 patients from the first study who received an additional year of deferasirox treatment or switched from placebo. Of the evaluable patients in this group, 35% achieved the target LIC.[35]

Correction of nutritional deficiencies

Nutritional deficiencies should be addressed and treated. A well-balanced diet with adequate folic acid supply is a necessity, and a folic acid supplement should be administered in those with folic acid deficiency. Foods with high iron content should be avoided, particularly meat, because heme iron is especially well absorbed. Vitamin C supplementation has been effective in enhancing the efficiency of chelating iron from tissues and assists absorption of dietary iron; therefore, patients should avoid co-ingesting vitamin C and iron-rich foods. Alternatively, drinking tea with iron-rich foods helps chelate some of the iron before it is absorbed in the bowels.

Antibiotic and vaccine prophylaxis

Appropriate vaccinations, including the polyvalent polysaccharide pneumococcal, the Haemophilus influenzae type b, and the quadrivalent meningococcal vaccines, should be administered to patients 1-2 weeks before splenectomy. Patients who have undergone a splenectomy should be placed on prophylactic antibiotics and be treated empirically for any signs of infection or fever while awaiting the results of blood cultures.

Patients with severe β thalassemia intermedia are prone to infection with Yersinia enterocolitica, similar to individuals with the severe forms of thalassemia major. For this reason, patients who develop fever without clear cause should receive appropriate treatment even if culture results are negative.

See the Medications section for more information on antimicrobial agents and vaccines.

Bone marrow transplantation

In patients with severe thalassemia intermedia who require aggressive therapy to sustain life, bone marrow transplantation, similar to that performed in patients with thalassemia major, is a reasonable alternative to transfusion and chelation if a matched sibling donor is available.

Previous
Next

Surgical Intervention

Placement of a central vascular access catheter in patients with severe disease is very helpful for blood transfusions, and laboratory work, especially when accessing a patient's peripheral veins becomes very difficult.

Splenectomy is frequently recommended for patients with thalassemia intermedia who are no longer able to maintain an adequate hemoglobin (Hb) level. It is usually performed to restore the Hb steady state in patients who are not receiving blood transfusions and frequently succeeds in averting the need for regular transfusions.

Observations and case reports have shown that splenectomy in such patients may cause serious venous thrombotic events, ranging from deep vein thrombosis (DVT) to pulmonary thrombotic lesions complicated by pulmonary hypertension.[14, 36, 37, 38] Owing to several reports of serious thrombotic events such as transient ischemic attacks (TIAs) associated with hemiparesis and intracranial manifestations of Moyamoya syndrome were reported postsplenectomy in patients with thalassemia intermedia,[38] one should delay or reconsider such a procedure whenever possible. This is supported by the fact that many children who underwent splenectomy to avoid becoming transfusion dependent experienced only a transient effect, and most required regular transfusions later.

Even though a good response to splenectomy is frequently encountered, it is occasionally unpredictable and could even be harmful. In a report, 2 transfusion-naïve siblings with thalassemia minor clinical conditions had deteriorated, becoming transfusion dependant shortly after they underwent splenectomy for enlarged spleens. One of the siblings also developed thrombotic events post splenectomy. The patients were found to have co-inherited a β+ thalassemia mutation together with a complete duplication of the α globin gene cluster on both alleles.[39]

In the rare patient with large tumorlike masses that compress vital organs, surgical resection rather than radiation therapy is usually preferred.[40]

Previous
Next

Complications

Most complications expected in thalassemia intermedia have been described previously. The conversion of thalassemia intermedia to a transfusion-dependent state is, by itself ,the most serious complication, because that marks the transition of thalassemia intermedia to a more severe form of β thalassemia.

As a result of the advanced care provided to patients with thalassemia, they are now surviving to an advanced age. With this longer survival comes new problems, which require a change in the approach to the care of affected patients. Three such complications recently been described as major issues in the adults with thalassemia: hepatitis C virus (HCV) infection, thrombotic events, and fertility issues.

HCV infection

HCV infection is a major complication of the lifelong blood transfusions in patients with the severe forms of thalassemia. This is probably less of a problem in patients with thalassemia intermedia who are not transfusion dependent. Nevertheless, HCV has also been reported in patients with thalassemia who have never had transfusions.

The incidence of positive HCV antibodies or RNA in patients aged 25 years or older (who were treated before the screening for HCV was initiated in 1990) was reported by the Thalassemia Clinical Research Network (TCRN) to be as high as 70% compared with only 5% in patients aged 15 years or younger.[41] The American Association of Blood Banks (AABB) has reported that the chance to contract HCV from blood transfusions in the United States is 1 per 1 million units transfused. Unfortunately, this is not the case in some developing countries where the rate was reported to be 63.8%.

HCV and iron overload are risk factors for cirrhosis and hepatocellular carcinoma (HCC); for this reason, many authors recommend monitoring such patients closely with liver ultrasonography and alpha fetoprotein level (AFP) levels. About 33% of patients with HCV in North America are expected to spontaneously clear the virus; if this does not occur, aggressive treatment should be initiated. Pegylated interferon alpha (INF-alpha), in combination with ribavirin, has been very effective in treating children with HCV infection.[42]

Thrombotic events

Thrombotic events have been increasingly encountered not only in patients with thalassemia intermedia but also in those with thalassemia major and β thalassemia/Hb E disease. In one study of 85 patients with thalassemia intermedia and 65 with thalassemia major, the incidence of venous thromboembolic events was 29% and 2%, respectively[14] ; 23 of the 24 patients with thalassemia intermedia and venous thromboembolic events had undergone splenectomy. For this reason, some recommend short-term antithrombotic therapy both perioperatively and when a risk factor for thrombosis exists. A low-dose daily aspirin is also recommended for all patients with thalassemia who are splenectomized and for those with thalassemia major and a platelet count of 600,000/μL after splenectomy.

The leading cause of morbidity and mortality in thalassemia major patients is cardiac siderosis. This is not the case in thalassemia intermedia patients, however, since pulmonary hypertension and thrombosis are the major forms of cardiovascular complications in this condition. Endothelial dysfunction in thalassemia intermedia is thought to play a major role in causing thrombotic events.

It has been suggested that patients with thalassemia intermedia exhibit a proatherogenic biochemical phenotype, which may contribute to the cardiovascular risk in thalassemia intermedia patients. The serum Fe level and Fe saturation were significantly higher in thalassemia intermedia than in both thalassemia major and normal controls. The hepcidin level, as well as the transferrin level, were also lower in thalassemia intermedia than in the thalassemia major and controls. Thalassemia intermedia patients also exhibit lower high-density lipoprotein and increased cytoplasmic neutral lipid values.[43]

Other complications

Fertility in adult patients with thalassemia is another new issue that providers have to deal with. Other complications that can arise include the following:

  • Hypersplenism: Severe thalassemia is often characterized by hypersplenism, which usually results in exaggerated anemia, thrombocytopenia, and enlarged abdomen
  • Iron overload, liver disease, and cardiac and endocrine defects are also encountered in this condition
  • Bone deformities, fractures, and neurologic complications from compression by tumorlike extramedullary hematopoietic tissue masses are more frequently observed in thalassemia intermedia than in thalassemia major, because the hyperactivity of the marrow in patients with untreated thalassemia intermedia is not suppressed by repeated blood transfusions
  • Complications of blood transfusions, such as hepatitis and other transmitted organisms, are all well known
Previous
Next

Long-Term Monitoring

Frequent outpatient visits are needed in the early stages of thalassemia intermedia to monitor the patient's hematologic parameters, activity, exercise tolerance, growth, and development of bone changes.

Once the patient requires regular transfusions, monthly outpatient visits for blood transfusions and laboratory work for monitoring iron load status are usually required. Guidelines for transfusion in neonates and older children have been established.[8]

While receiving chelation therapy, patients should have eye examinations and hearing tests as part of monitoring for the complications of therapy.

Young children should have their growth and development closely monitored; any deviation from normal should alert the physician to further investigate the need for blood transfusions. Failure to thrive, exercise intolerance, bone deformities and fractures are all potential complications; the healthcare provider should always look for ways to prevent these complications or at least identify and treat them early with regular blood transfusions, which are frequently effective in reversing or preventing their progress.

Previous
 
 
Contributor Information and Disclosures
Author

Hassan M Yaish, MD Medical Director, Intermountain Hemophilia and Thrombophilia Treatment Center; Professor of Pediatrics, University of Utah School of Medicine; Director of Hematology, Pediatric Hematologist/Oncologist, Department of Pediatrics, Primary Children's Medical Center

Hassan M Yaish, MD is a member of the following medical societies: American Academy of Pediatrics, New York Academy of Sciences, American Medical Association, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Michigan State Medical Society

Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD Director, Children’s Center for Cancer and Blood Disorders, Department of Hematology/Oncology, Co-Director of the Ron Matricaria Institute of Molecular Medicine, Phoenix Children’s Hospital; Editor-in-Chief, Pediatric Blood and Cancer; Professor, Department of Child Health, University of Arizona College of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Acknowledgements

James L Harper, MD Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Assistant Clinical Professor, Department of Pediatrics, Creighton University; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center

James L Harper, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Federation for Clinical Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Council on Medical Student Education in Pediatrics, and Hemophilia and Thrombosis Research Society

Disclosure: Nothing to disclose.

J Martin Johnston, MD Associate Professor of Pediatrics, Mercer University School of Medicine; Director of Pediatric Hematology/Oncology, Backus Children's Hospital; Consulting Oncologist/Hematologist, St Damien's Pediatric Hospital

J Martin Johnston, MD is a member of the following medical societies: American Academy of Pediatrics and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

References
  1. Li Q, Li LY, Mo QH. [A rare thalassemia intermedia case caused by co-existence of Hb H disease (--(SEA)/-alpha(4.2)) and beta-thalassemia major (beta (CD17A)>T/beta (IVS2-654C)>T): implications for prenatal diagnosis]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jan. 28(1):16-9. [Medline].

  2. Haghi M, Feizi AA, Harteveld CL, Pouladi N, Feizi MA. Homozygosity for a rare beta 0-thalassemia mutation [frameshift codons 25/26 (+T)] causes beta-thalassemia intermedia in an Iranian family. Hemoglobin. 2009. 33(1):75-80. [Medline].

  3. Harteveld CL, Refaldi C, Cassinerio E, Cappellini MD, Giordano PC. Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. Blood Cells Mol Dis. 2008 May-Jun. 40(3):312-6. [Medline].

  4. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007 Jun 1. 109(11):5027-35. [Medline].

  5. Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol. 2006 Oct. 135(1):129-38. [Medline].

  6. Finkenstedt A, Bianchi P, Theurl I, Vogel W, Witcher DR, Wroblewski VJ, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol. 2009 Mar. 144(5):789-93. [Medline].

  7. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with ß thalassemia intermedia. Blood Cells Mol Dis. 2011 Dec 15. 47(4):232-4. [Medline].

  8. [Guideline] Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004 Feb. 124(4):433-53. [Medline].

  9. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007 May. 92(5):583-8. [Medline]. [Full Text].

  10. Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011 Dec 1. 121(12):4880-8. [Medline]. [Full Text].

  11. Uzun E, Balcı YI, Yuksel S, Aral YZ, Aybek H, Akdag B. Glomerular and tubular functions in children with different forms of beta thalassemia. Ren Fail. 2015 Sep 12. 1-5. [Medline].

  12. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007 May. 92(5):658-65. [Medline].

  13. Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011. 3(1):e2011025. [Medline]. [Full Text].

  14. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci. 2005. 1054:317-24. [Medline].

  15. Dunn J, Khan S, Ariff B, Strickland N, Al-Nahhas A. Pulmonary emboli and extramedullary haematopoiesis in beta-thalassaemia intermedia. Nucl Med Rev Cent East Eur. 2008. 11(1):34-6. [Medline].

  16. Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am J Hematol. 2008 Jan. 83(1):77-9. [Medline].

  17. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008 Nov. 8(7):620-32. [Medline].

  18. Parker TM, Ward LM, Johnston DL, Ventureya E, Klaassen RJ. A case of Moyamoya syndrome and hemoglobin E/beta-thalassemia. Pediatr Blood Cancer. 2009 Mar. 52(3):422-4. [Medline].

  19. Metarugcheep P, Chanyawattiwongs S, Srisubat K, Pootrakul P. Clinical silent cerebral infarct (SCI) in patients with thalassemia diseases assessed by magnetic resonance imaging (MRI). J Med Assoc Thai. 2008 Jun. 91(6):889-94. [Medline].

  20. Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008 Jul. 142(1):126-35. [Medline].

  21. Goldschmidt N, Spectre G, Brill A, et al. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost. 2008 Nov. 100(5):864-70. [Medline].

  22. Singer ST, Ataga KI. Hypercoagulability in sickle cell disease and beta-thalassemia. Curr Mol Med. 2008 Nov. 8(7):639-45. [Medline].

  23. Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and ß-thalassemia in Saudi Arabia. Ann Saudi Med. 2011 May-Jun. 31(3):229-35. [Medline]. [Full Text].

  24. Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of ß-thalassemia can help to predict the major or intermedia type of the disease. Haematologica. 2011 Nov. 96(11):1712-4. [Medline]. [Full Text].

  25. Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009 May 14. 113(20):4853-5. [Medline]. [Full Text].

  26. Wood JC, Mo A, Gera A, Koh M, Coates T, Gilsanz V. Quantitative computed tomography assessment of transfusional iron overload. Br J Haematol. 2011 Jun. 153(6):780-5. [Medline].

  27. Deborah Chirnomas S, Geukes-Foppen M, Barry K, Braunstein J, Kalish LA, Neufeld EJ, et al. Practical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemias. Am J Hematol. 2008 Oct. 83(10):781-3. [Medline].

  28. Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011 Sep 12. 13:45. [Medline]. [Full Text].

  29. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005 Jul. 27(7):380-5. [Medline].

  30. Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008 May. 83(5):366-70. [Medline].

  31. Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. 2011 Jul 28. 118(4):1109-12. [Medline]. [Full Text].

  32. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008 Dec. 22 Suppl 2:S35-41. [Medline].

  33. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011 Jul 28. 118(4):884-93. [Medline].

  34. Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012 Aug 2. 120(5):970-7. [Medline].

  35. Taher AT, Porter JB, Viprakasit V et al. Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia: a one-year, open-label extension to a one-year, randomized double-blind, placebo-controlled study (THALASSA). Poster presented at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, GA (8-11 December 2012). Abstract #3258.

  36. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003 Apr. 77(3):299-303. [Medline].

  37. Blendis LM, Modell CB, Bowdler AJ. Some effects of splenectomy in thalassaemia major. Br J Haematol. 1974 Sep. 28(1):77-87. [Medline].

  38. Sanefuji M, Ohga S, Kira R, et al. Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. J Child Neurol. Jan 2006. 21(1):75-7. [Medline].

  39. Graziadei G, Refaldi C, Barcellini W, et al. Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?. Haematologica. 2012 Jan. 97(1):151-3. [Medline]. [Full Text].

  40. Luyendijk W, Went L, Schaad HD. Spinal cord compression due to extramedullary hematopoiesis in homozygous thalassemia. Case report. J Neurosurg. 1975 Feb. 42(2):212-6. [Medline].

  41. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood. 2004 Jul 1. 104(1):34-9. [Medline].

  42. Davison SM, Kelly DA. Management strategies for hepatitis C virus infection in children. Paediatr Drugs. 2008. 10(6):357-65. [Medline].

  43. Lai ME, Vacquer S, Carta MP, et al. Thalassemia intermedia is associated with a proatherogenic biochemical phenotype. Blood Cells Mol Dis. 2011 Apr 15. 46(4):294-9. [Medline].

  44. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions?. Transfusion. 2007 May. 47(5):792-800. [Medline].

  45. The thalassemia syndromes. Nathan DG, Oski FA, eds. Nathan and Oski's Hematology of Infancy and Childhood. 5th ed. Philadelphia, Pa: WB Saunders Co; 1997. Vol 1: 847-9.

  46. The thalassemias. Lilleyman JS, Hann IM, Blanchette V, eds. Pediatric Hematology. 2nd ed. 2000. 316, 325.

  47. Weatherall DJ. Thalassemia. Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds. The Molecular Basis of Blood Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994. 157-206.

  48. Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 3rd ed. Oxford, England: Blackwell Science Publishing Co; 1981.

 
Previous
Next
 
Peripheral blood film in thalassemia intermedia.
Basophilic stippling in thalassemia intermedia.
Nucleated red blood cell in thalassemia intermedia.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.